A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670).

Trial Profile

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670).

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2014

At a glance

  • Drugs Ficlatuzumab (Primary)
  • Indications Liver metastases; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 01 Oct 2012 Results have been presented at ESMO-2012 according to an AVEO Oncology media release.
    • 14 Apr 2012 Additional lead trial investigator (Shefali Agarwal) identified as reported by ClinicalTrials.gov.
    • 14 Apr 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top